Incidentally, if you really are investing in AZN, you should know that they are a classic value trap. Although they pay a fat dividend, their earnings are falling and will fall much further. Of their top four drugs, the patents on two -Seroquel and Symbicort - expired this year. The patent on their big winner, Nexium, expires next year. Only Crestor has much life left ; its patent expires in 2016, but generic Lipitor will make it irrelevant.